Gilead

California Supreme Court ruled in favor of Gilead in a duty-to-innovate case, potentially easing liability risk for slow-walking drug development while underscoring industry concern about how litigation could influence R&D decisions.

The TIGIT drug program hype collapsed after billions spent and multiple late-stage failures across Roche, Merck, Beigene, GSK/iTeos, and others, with regulators granting and later debunking designations, culminating in a broad industry shift away from Fc-active/ Fc-silent TIGIT strategies and a surviving asset only in AstraZeneca’s rilvegostomig.